AQST-109 is the first and only orally delivered epinephrine product candidate in clinical development
Fastest median time to maximum concentration (Tmax) in studies to date at 12 minutes
Study continues to show AQST-109 is safe and well tolerated
Head-to-head comparison study to EpiPen® scheduled to commence in third quarter 2022
On track to request End-of-Phase 2 meeting with FDA in fourth quarter 2022 and thereafter to commence pivotal PK study
Remaining data from Part 3 expected to be reported in early third quarter 2022
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.